Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040
By Adriano Marchese
Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.
Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.
Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.
Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.
Dr. Reddy's wasn't readily available for comment.
Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 03, 2025 08:57 ET (12:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States